Infections with shiga toxin-producing bacteria, like enterohemorrhagic Escherichia coli and Shigella dysenteriae, represent a serious medical problem. No specific and effective treatment is available for patients with these infections, creating a need for the development of new therapies. Recombinant lactic acid bacterium Lactococcus lactis was engineered to bind Shiga toxin by displaying novel designed albumin binding domains (ABD) against Shiga toxin 1 B subunit (Stx1B) on their surface. Functional recombinant Stx1B was produced in Escherichia coli and used as a target for selection of 17 different ABD variants (named S1B) from the ABD scaffold-derived high-complex combinatorial library in combination with a five-round ribosome display. Two most promising S1Bs (S1B22 and S1B26) were characterized into more details by ELISA, surface plasmon resonance and microscale thermophoresis. Addition of S1Bs changed the subcellular distribution of Stx1B, completely eliminating it from Golgi apparatus most likely by interfering with its retrograde transport. All ABD variants were successfully displayed on the surface of L. lactis by fusing to the Usp45 secretion signal and to the peptidoglycan-binding C terminus of AcmA. Binding of Stx1B by engineered lactococcal cells was confirmed using flow cytometry and whole cell ELISA. Lactic acid bacteria prepared in this study are potentially useful for the removal of Shiga toxin from human intestine.

Department of Biology Biotechnical Faculty University of Ljubljana Jamnikarjeva 101 1000 Ljubljana Slovenia

Department of Biotechnology Jožef Stefan Institute Jamova 39 SI 1000 Ljubljana Slovenia

Laboratory of Ligand Engineering Institute of Biotechnology CAS v v i BIOCEV Research Center Průmyslová 595 252 50 Vestec Czech Republic

National Institute of Chemistry Hajdrihova 19 1000 Ljubljana Slovenia

The Chair of Pharmaceutical Biology Faculty of Pharmacy University of Ljubljana Aškerčeva 7 SI 1000 Ljubljana Slovenia

Zobrazit více v PubMed

Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing PubMed PMC

O`Brien AD, Holmes RK. Shiga and Shiga-Like Toxins. Microbiol Rev. 1987;51(2):206–20. PubMed PMC

Johannes L, Römer W. Shiga toxins—from cell biology to biomedical applications. Nat Rev Microbiol. 2010. 10.1038/nrmicro2279 PubMed DOI

Keir LS, Marks SD, Kim JJ. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther. 2012;6:195–208. . PubMed PMC

Sandvig K, van Deurs B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev. 1996;76(4):949–66. . PubMed

Sandvig K. Shiga toxins. Toxicon. 2001;39(11):1629–35. 10.1016/S0041-0101(01)00150-7 . PubMed DOI

Melton-Celsa AR, O'Brien AD. New Therapeutic Developments against Shiga Toxin-Producing Escherichia coli. Microbiol Spectr. 2014;2(5). 10.1128/microbiolspec.EHEC-0013-2013 . PubMed DOI

Rahal EA, Fadlallah SM, Nassar FJ, Kazzi N, Matar GM. Approaches to treatment of emerging Shiga toxin-producing PubMed DOI PMC

Skrlec K, Strukelj B, Berlec A. Non-immunoglobulin scaffolds: a focus on their targets. Trends Biotechnol. 2015;33(7):408–18. 10.1016/j.tibtech.2015.03.012 . PubMed DOI

Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. 2009;13(3):245–55. 10.1016/j.cbpa.2009.04.627 . PubMed DOI

Ahmad JN, Li J, Biedermannova L, Kuchar M, Sipova H, Semeradtova A, et al. Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G. Proteins. 2012;80(3):774–89. 10.1002/prot.23234 . PubMed DOI

Kuchar M, Vankova L, Petrokova H, Cerny J, Osicka R, Pelak O, et al. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells. Proteins. 2014;82(6):975–89. 10.1002/prot.24472 . PubMed DOI PMC

Mareckova L, Petrokova H, Osicka R, Kuchar M, Maly P. Novel binders derived from an albumin-binding domain scaffold targeting human prostate secretory protein 94 (PSP94). Protein Cell. 2015. 10.1007/s13238-015-0194-9 . PubMed DOI PMC

Mohsin M, Guenther S, Schierack P, Tedin K, Wieler LH. Probiotic PubMed DOI

Reissbrodt R, Hammes WP, dal Bello F, Prager R, Fruth A, Hantke K, et al. Inhibition of growth of Shiga toxin-producing PubMed DOI

Ogawa M, Shimizu K, Nomoto K, Tanaka R, Hamabata T, Yamasaki S, et al. Inhibition of in vitro growth of Shiga toxin-producing PubMed

Ravnikar M, Strukelj B, Obermajer N, Lunder M, Berlec A. Engineered Lactic Acid Bacterium PubMed DOI PMC

Zadravec P, Strukelj B, Berlec A. Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of PubMed DOI PMC

Zadravec P, Strukelj B, Berlec A. Heterologous surface display on lactic acid bacteria: non-GMO alternative? Bioengineered. 2015;6(3):179–83. 10.1080/21655979.2015.1040956 . PubMed DOI PMC

Steen A. Cell Wall Attachment of a Widely Distributed Peptidoglycan Binding Domain Is Hindered by Cell Wall Constituents. J Biol Chem. 2003;278(26):23874–81. 10.1074/jbc.M211055200 PubMed DOI

Buist G, Kok J, Leenhouts KJ, Dabrowska M, Venema G, Haandrikman AJ. Molecular cloning and nucleotide sequence of the gene encoding the major peptidoglycan hydrolase of PubMed PMC

Steen A, Buist G, Horsburgh GJ, Venema G, Kuipers OP, Foster SJ, et al. AcmA of PubMed DOI

Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic PubMed

Pinyon RA, Paton JC, Paton AW, Botten JA, Morona R. Refinement of a therapeutic Shiga toxin-binding probiotic for human trials. J Infect Dis. 2004;189(9):1547–55. 10.1086/383417 . PubMed DOI

Bondos SE, Bicknell A. Detection and prevention of protein aggregation before, during, and after purification. Anal Biochem. 2003;316(2):223–31. 10.1016/S0003-2697(03)00059-9 . PubMed DOI

Tsumoto K, Ejima D, Kumagai I, Arakawa T. Practical considerations in refolding proteins from inclusion bodies. Protein Expr Purif. 2003;28(1):1–8. 10.1016/S1046-5928(02)00641-1 . PubMed DOI

Oneda H, Inouye K. Refolding and recovery of recombinant human matrix metalloproteinase 7 (matrilysin) from inclusion bodies expressed by PubMed

de Ruyter PG, Kuipers OP, de Vos WM. Controlled gene expression systems for PubMed PMC

Kuipers OP, Beerthuyzen MM, Siezen RJ, De Vos WM. Characterization of the nisin gene cluster nisABTCIPR of PubMed

Kuipers OP, de Ruyter PGGA, Kleerebezem M, de Vos WM. Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol. 1998;64(1):15–21. 10.1016/S0168-1656(98)00100-X DOI

Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in PubMed DOI

Ashkenazi S, Cleary TG. Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor. J Clin Microbiol. 1989;27(6):1145–50. . PubMed PMC

Berlec A, Malovrh T, Zadravec P, Steyer A, Ravnikar M, Sabotic J, et al. Expression of a hepatitis A virus antigen in PubMed DOI

Berlec A, Zadravec P, Jevnikar Z, Strukelj B. Identification of candidate carrier proteins for surface display on PubMed DOI PMC

Zadravec P, Mavric A, Bogovic Matijasic B, Strukelj B, Berlec A. Engineering BmpA as a carrier for surface display of IgG-binding domain on PubMed DOI

Lindholm A, Smeds A, Palva A. Receptor binding domain of PubMed PMC

Kim JH, Lingwood CA, Williams DB, Furuya W, Manolson MF, Grinstein S. Dynamic measurement of the pH of the Golgi complex in living cells using retrograde transport of the verotoxin receptor. J Cell Biol. 1996;134(6):1387–99. . PubMed PMC

Neri P, Shigemori N, Hamada-Tsutsumi S, Tsukamoto K, Arimitsu H, Shimizu T, et al. Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library. Vaccine. 2011;29(33):5340–6. 10.1016/j.vaccine.2011.05.093 . PubMed DOI

Lipovsek D, Pluckthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods. 2004;290(1–2):51–67. 10.1016/j.jim.2004.04.008 . PubMed DOI

Richter A, Eggenstein E, Skerra A. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett. 2014;588(2):213–8. 10.1016/j.febslet.2013.11.006 . PubMed DOI

Dieye Y, Usai S, Clier F, Gruss A, Piard JC. Design of a protein-targeting system for lactic acid bacteria. J Bacteriol. 2001;183(14):4157–66. 10.1128/JB.183.14.4157-4166.2001 . PubMed DOI PMC

Targeting Human Thrombus by Liposomes Modified with Anti-Fibrin Protein Binders

Engineered Lactococcus lactis Secreting IL-23 Receptor-Targeted REX Protein Blockers for Modulation of IL-23/Th17-Mediated Inflammation

ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis